THE CLINICAL EFFECT OF ISONIAZID AND IPRONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSIS
Authors: R G BLOCH, A S DOONEIEF, A S BUCHBERG, S SPELLMAN
Journal: Annals of Internal Medicine (1954)

Article1 May 1954THE CLINICAL EFFECT OF ISONIAZID AND IPRONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSISROBERT G. BLOCH, M.D., F.A.C.P., ALFRED S. DOONEIEF, M.D., ABRAHAM S. BUCHBERG, M.D., STANLEY SPELLMAN, M.D.ROBERT G. BLOCH, M.D., F.A.C.P., ALFRED S. DOONEIEF, M.D., ABRAHAM S. BUCHBERG, M.D., STANLEY SPELLMAN, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-40-5-881 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince the hydrazine derivatives of isonicotinic acid were first advocated as effective against tuberculosis early in 1952, there has been much serious appraisal of their therapeutic value. Isoniazid already has taken an important place in phthisiotherapy, if only because of the ease of its application and the small expense of the drug. But there is a need for extensive and prolonged clinical experimentation before the encouraging results of scarcely one year can be confirmed. Much of the early publicity campaign in the daily press about the new "miracle drugs" still lingers on, in the minds not only of the public...Bibliography1. RobitzekSelikoffOrnstein EHIJGG: Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid, Quart. Bull., Sea View Hosp. 13: 21, 1952. Google Scholar2. RobitzekSelikoff EHIJ: Hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis, Am. Rev. Tuberc. 65: 402, 1952. MedlineGoogle Scholar3. SelikoffRobitzekOrnstein IJEHGG: Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid, J. A. M. A. 150: 973, 1952. CrossrefMedlineGoogle Scholar4. JoinerMacLeanPritchardAndersonCollard CLKSEKKP: Isoniazid in pulmonary tuberculosis, its use with and without streptomycin, Lancet 2: 843, 1952. CrossrefMedlineGoogle Scholar5. CollinsBowen DMDA: Isoniazid in the treatment of pulmonary tuberculosis, Tubercle 34: 8, 1953. CrossrefMedlineGoogle Scholar6. Knox R: Resistance to isoniazid, Lancet 1: 443, 1953. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication September 11, 1953.From the Division of Pulmonary Diseases, Montefiore Hospital, N. Y., and the Westchester Division, Montefiore Hospital, Bedford Hills, N. Y.Read at the 48th Annual Meeting of The American Trudeau Society in Los Angeles, May, 1952.We wish to express our appreciation to Hoffmann-LaRoche, Inc., Nutley, New Jersey, for generously supplying us with the drugs used in this investigation.†Teaching-Resident Fellow of the National Tuberculosis Association. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDiscovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A ReviewFrom the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic EraAntidepressantsAstrocyte, a Promising Target for Mood Disorder InterventionsHow good are publicly available web services that predict bioactivity profiles for drug repurposing?Antibiotics and mania: A systematic reviewNovel Targets for Drug Treatment in PsychiatryTraditional and Novel Possible Targets for Antidepressant DrugsCNS DrugsSchizophrenia and Affective DisordersDepression: An Evolutionary Adaptation Organised Around the Third VentriclePharmacology and neuroimaging of antidepressant actionAntidepressants in counselling psychology: Relevance, effectiveness and implications for practiceSerendipity and PsychopharmacologyAntidepressantsDepression as an evolutionary adaptation: Anatomical organisation around the third ventricleDepressionDepression: Phenomenology, Epidemiology, and PathophysiologyAntidepressants: will new mechanisms of action improve poor outcomes?Forced swimming test in mice: a review of antidepressant activityFrom monoamines to genomic targets: a paradigm shift for drug discovery in depressionAntidepressantsAmine neurochemistry and aggression in crayfishMonoamine Oxidase InhibitorsAntimicrobial-Induced Mania (Antibiomania): A Review of Spontaneous ReportsPharmacotherapy of Affective DisordersPharmakotherapie affektiver StörungenRecent developments in antidepressant agentsColumbia Atypical DepressionAbuse of Monoamine Oxidase InhibitorsDrug-Induced Mania - Causative Agents,Clinical Characteristics and ManagementThe newer antidepressants: Promises and realitiesTraumatic War Neuroses: Some Pharmacologic and Psychophysiologic ObservationsIs there a hypoxic affective syndrome?The Behavioral Toxicity of Monoamine Oxidase-lnhibiting AntidepressantsThe relationship of early studies of monoamine oxidase to present conceptsIPRONIAZID IN THE TREATMENT OF RESISTANT HYPERTENSIONMonoaminoxydase-HemmerTREATMENT OF HOSPITALIZED MENTAL PATIENTS WITH IPRONIAZID*IPRONIAZID IN THE ANGINAL SYNDROME DUE TO CORONARY DISEASEHepatitis associated with iproniazid (Marsilid®)Jaundice associated with the administration of iproniazidIproniazid (Marsilid) in angina pectorisLiver Damage Concurrent with Iproniazid AdministrationAndere ChemotherapeutikaAndere ChemotherapeutikaFATAL TOXIC ENCEPHALITIS OCCURRING DURING IPRONIAZID THERAPY IN PULMONARY TUBERCULOSIS*ROGER S. MITCHELL, M.D., F.A.C.P. 1 May 1954Volume 40, Issue 5Page: 881-900KeywordsDrugsIsoniazidPulmonary diseases ePublished: 1 December 2008 Issue Published: 1 May 1954 PDF downloadLoading ...